Risk stratification for acute coronary syndrome by determining copeptin
The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
1. A method for risk stratification of acute coronary syndrome, comprising determining the level of copeptin in at least one sample from a patient, wherein a threshold level of copeptin of 10-30 pmol/L in said at least one sample indicates an increased risk of or an unfavorable prognosis of acute coronary syndrome for said patient.
2. The method of claim 1 , wherein said threshold level is 10-20 pmol/L of copeptin.
3. The method of claim 1 , wherein said patient is an asymptomatic patient or a symptomatic patient showing symptoms of acute coronary syndrome.
4. The method of claim 1 , wherein said method further comprises determining the level of at least one additional marker selected from the group consisting of inflammatory markers, cardiovascular markers, neurohormonal markers, and ischemic markers in at least one sample from said patient.
5. The method of claim 4 , wherein
the inflammatory marker is selected from the group consisting of C-reactive protein (CRP), cytokines and adhesion molecules; or
the cardiovascular marker is at least one marker selected from the group consisting of creatin kinase, myoglobin, myeloperoxidase, a natriuretic protein, cardiac troponin, CRP, circulation-regulating (pro)hormones, and partial sequences thereof.
6. The method of claim 4 , wherein
the ischemic marker is at least one marker selected from the group consisting of troponin I and T, and CK-MB; or
the neurohormonal marker is at least one natriuretic protein or a partial sequence thereof.
7. A method for diagnosis of acute coronary syndrome, comprising determining the level of copeptin in at least one sample from a patient, wherein a threshold level of copeptin of 6-20 pmol/L in said at least one sample indicates the presence in said patient of acute coronary syndrome.
8. The method of claim 7 , wherein said threshold level is 6-10 pmol/L of copeptin.
9. The method of claim 7 , wherein said patient is an asymptomatic patient or a symptomatic patient showing symptoms of acute coronary syndrome.
10. The method of claim 7 , wherein said method further comprises determining the level of a natriuretic protein or a partial sequence thereof in at least one sample from said patient.
11. The method of claim 7 , wherein said method further comprises determining the level of at least one additional marker selected from the group consisting of inflammatory markers, cardiovascular markers, neurohormonal markers, and ischemic markers in at least one sample from said patient.
12. The method of claim 11 , wherein
the inflammatory marker is selected from the group consisting of C-reactive protein (CRP), cytokines and adhesion molecules; or
the cardiovascular marker is at least one marker selected from the group consisting of creatin kinase, myoglobin, myeloperoxidase, a natriuretic protein, cardiac troponin, CRP, circulation-regulating (pro)hormones, and partial sequences thereof.
13. The method of claim 11 , wherein
the ischemic marker is at least one marker selected from the group consisting of troponin I and T, and CK-MB; or
the neurohormonal marker is at least one natriuretic protein or a partial sequence thereof.